IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Brian D. Follstad

Serial No.:

10/620,064

Filed:

July 15, 2003

OCT 1 4 2005

Group Art Unit No.: 1651

Examiner: L. Lankford, Jr.

METHODS AND MEDIAMED CONTROLLING SIALYLATION OF PROTEINS

For:

PRODUCED BY MAMMALIAN CELLS

Docket No.: 3374-A

INFORMATION DISCLOSURE STATEMENT BEFORE MAILING DATE OF EITHER A FINAL ACTION OR NOTICE OF ALLOWANCE (37 CFR 1.97(c))

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

As a means of complying with the duty of disclosure, applicant submits a "List of References Cited by Applicant" on a modified PTO-1449 form and provides a copy of each of the listed references for consideration by the Examiner. This Information Disclosure Statement is being filed after three months of the filing date of this national application or the date of entry of the national stage as set forth in § 1.491 in an international application or after the mailing date of the first Office action on the merits, whichever event occurred last, but **before** the mailing date of either:

(1) a final action under § 1.113 or

10/17/2005 HTECKLU1 00000026 090089 10620064

01 FC:1806

(2) a notice of allowance under § 1.311.

whichever occurs first.

180.00 DA

STATEMENT OR FEE

Accompanying this transmittal is:

a statement as specified in 37 CFR 1.97(e):

OR

 \boxtimes the fee set forth in 37 CFR 1.17(p) for submission of an information disclosure B. statement under § 1.97(c). (\$180.00).

Applicant requests consideration of this information and passage of the application to issue.

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date appearing below.

FEE PAYMENT

Please charge Deposit Account No. 09-0089 in the amount of \$180.00 (37 CFR 1.97(c)). An original and one copy are enclosed.

The Commissioner is hereby authorized to charge any additional fees which may be required or credit any overpayment to Deposit Account No. 09-0089.

Respectfully submitted,

RosemanySweeney

Attorney/Agent for Applicant Registration No.: 52,264

Jalemung Sweening

Phone: (206) 265-7817 Date: October 11, 2005

Please send all future correspondence to:

Immunex Corporation Law Department 1201 Amgen Court West Seattle, Washington 98119-3105 (206) 265-7000

gj101001 10/11/05

010		Sheet 1 Of 1
Modified Form PTO-1449	Atty. Docket No.	Serial No.
2005 8	3374-A	10/620.064
LIST OF REFERENCES CITED BY APPLICANT	Applicant	
LIST OF REFERENCES CITED BY APPLICANT	Brian D. Follstad	
(Use several sheets if necessary)	Filing Date	Group
	July 15, 2003	1651

U.S. PATENT DOCUMENTS

EXAMINER'S INITIALS		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
	A1						
	A2						
	А3						
	A4						
	A 5		,				
	A 6						

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSI YES	ATION NO
B1							
B2							
В3							
B4							
B5							

OTHER DOCUMENTS (Including Publisher, Author, Title, Date, Pertinent Pages, Etc.)

	C1	Kaufmann, H. et al., "Comparative analysis of two controlled proliferation strategies regarding product quality, influence on tetracycline-regulated gene expression, and productivity," <i>Biotechnology And Bioengineering</i>
		<i>72(6)</i> :592-602, 2001.
	C2	Kawaguchi, T. et al., "A new approach to the modification of cell membrane glycosphingolipids: ganglioside
		composition of JTC-12 P3 cells altered by feeding with galactose as a sole carbohydrate source in protein-free
		and lipid-free synthetic medium," Exp. Cell Res. 179(2):507-516, 1988.
	СЗ	Keppler, O. et al., "UDP-GlcNAc 2-Epimerase: A regulator of cell surface sialylation," Sci.284:1372-1376, 1999.
	C4	Miller-Podraza, H. et al., "Biosynthesis and localization of gangliosides in cultured cells," Biochem. 21(14):3260-
		3265, 1982.
	C5	Stephanopoulos, G. and Vallino, J., "Network rigidity and metabolic engineering in metabolite overproduction,"
		Science 252:1675-1681, 1991.
	C6	Vriezen, N. and van Dijken, J., "Fluxes and enzyme activities in central metabolism of myeloma cells grown in
		chemostat culture," Biotech. & Bioeng. 59(1):28-39, 1998.
	C 7	Wang, D., "Engineering of CHO cell glycosylation through CMP-Sialic acid transporter over expression,"
		Biochemical Engineering XIV, Session VI – Physiology of Protein Expression, Engineering Conferences
		International, Harrison Hot Springs, BC, Canada, July 10-14, 2005.
	C8	Yoon Sung Kwan et al., "Effect of low culture temperature on specific productivity and transcription level of anti-
		4-1BB antibody in recombinant Chinese hamster ovary cells," Biotech. Progress 19(4):1383-1386, 2003.
	C9	Zanghi, J. et al., "Role of nucleotide sugar pools in the inhibition of NCAM polysialylation by ammonia," Biotech.
		Progress 14(6):834-844, 1998.
EXAMINER:		Date Considered:

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.